BTIG downgraded Shattuck Labs to Neutral from Buy. The firm noted that updated interim data for 1L HR-MDS and TP53m AML showed encouraging efficacy. BTIG added that ambiguity around the benefit from CD47-CD40 will remain until the second half of next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs Reports Promising Cancer Trial Outcomes
- Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
- Shattuck Labs announces ODD granted by FDA for SL-172154
- Shattuck Labs treatment of acute myeloid leukemia granted orphan designation